Abstract
Being a rare entity, GISTs represents the most common subset of mesenchymal tumours that arise from the digestive tract. Their immunohistochemical and histopathologic features distinguish them from other gastrointestinal mesenchymal neoplasms. These tumours have been the matter of considerable debate in the literature regarding their histogenesis, criteria for diagnosis, prognostic features and treatment. GISTs express Kit protein that not only is a marker for diagnosis but has also permitted to identify a specific medical treatment. The exceptional interest aroused in the literature leads us to make a review about this subject reporting five cases treated in the last 2 years.
Publication types
-
Case Reports
-
Comparative Study
-
Review
MeSH terms
-
Aged
-
Antineoplastic Agents / therapeutic use
-
Benzamides
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Female
-
Follow-Up Studies
-
Gastrointestinal Stromal Tumors* / diagnosis
-
Gastrointestinal Stromal Tumors* / diagnostic imaging
-
Gastrointestinal Stromal Tumors* / drug therapy
-
Gastrointestinal Stromal Tumors* / mortality
-
Gastrointestinal Stromal Tumors* / pathology
-
Gastrointestinal Stromal Tumors* / surgery
-
Humans
-
Imatinib Mesylate
-
Immunohistochemistry
-
Male
-
Middle Aged
-
Piperazines / therapeutic use
-
Protein Kinase Inhibitors / therapeutic use
-
Proto-Oncogene Proteins c-kit / analysis
-
Pyrimidines / therapeutic use
-
Radiography, Abdominal
-
Time Factors
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Imatinib Mesylate
-
Proto-Oncogene Proteins c-kit